A new UK initiative aims to transform used nuclear materials into cutting-edge cancer treatments, following a £9.9 million ($12.99 million) investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP) and an additional £8.9 million from industry partners.
The project centers on harvesting the radionuclide lead-212 from recycled nuclear fuel to support the development of Targeted Alpha Therapies—an emerging class of radiopharmaceuticals designed to attack cancer cells with high precision and minimal impact on healthy tissue.
Led by the United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the initiative positions Britain to become a global leader in a rapidly expanding area of cancer innovation.
Turning Nuclear Fuel into Medical Isotopes
UKNNL has developed a process to extract lead-212 from material originating from nuclear fuel previously used to power homes across the UK. A minute fraction of parent material is isolated—“equivalent to a single drop of water in an Olympic-sized swimming pool”—followed by the extraction of an even smaller amount of lead-212. According to project leaders, properly developed radiopharmaceuticals derived from this supply could support thousands of patient treatments.
The UK holds significant reserves of this isotope, offering the potential for a scalable and sustainable supply chain. The initiative aims to create the necessary infrastructure to support clinical trials and, ultimately, large-scale deployment of these therapies.
Government and Industry Leaders Voice Support
The project has drawn strong endorsements from senior political and scientific figures.
Science and Technology Secretary Liz Kendall described the program as an example of UK innovation delivering tangible hope for cancer patients. “It’s incredible to think that we could turn used nuclear fuel into cutting-edge cancer treatments – but that is exactly what British scientific brilliance is making possible,” she said. “Remarkable work like this… shows precisely why this Government is giving record funding to research and development.”
Julianne Antrobus, Chief Executive Officer at UKNNL, highlighted the potential impact on both healthcare and nuclear innovation. “Through access to the UK’s sovereign supply of lead-212, we have a truly unique opportunity to transform our nuclear expertise into life-saving cancer treatments,” she said. “Developed from recycled fuel… lead-212 can now serve us again by offering new hope to cancer patients.”
Professor Chris Molloy, CEO of Medicines Discovery Catapult, called lead-212 “an untapped national asset with extraordinary medical potential,” noting that the new investment “is a clear signal that the UK is ready to innovate for patients here and around the world.”
Dr Mark Talford of Innovate UK emphasized the sustainability aspect, saying the project demonstrates “how sustainability and science can work hand in hand” by repurposing legacy nuclear materials for modern therapeutic applications.
Expanding a Radiopharmaceutical Ecosystem
Beyond UKNNL and MDC, the program brings together a consortium of seven specialist organizations spanning nuclear engineering, radiochemistry, biotherapeutics, and pharmaceutical development. These include Cyclife Aquila Nuclear, PentaBind, Iksuda Therapeutics, Seda, and entX. Their combined role encompasses technology development, production processes, preclinical testing, and preparing the therapies for regulatory evaluation.
Consortium members emphasized the collaborative opportunity. Claire Patterson of Seda said the company was “proud to form part of this pioneering project in an area which is receiving significant attention.”
PentaBind’s Chief Technology Officer Phil Haynes noted the potential for precision: “PentaBind is building an AI-driven aptamer platform to direct radiation to cancer cells with true precision.”
Julian Kelly of entX described the program as “a vital stepping-stone in unlocking an ultra-reliable UK source of therapeutic isotope precursor,” while Drew Corbett of Cyclife Aquila Nuclear highlighted the sustainability impact of “turning what was once considered nuclear waste into precision cancer treatments.”
Strengthening the UK’s Position in Nuclear and Medical Innovation
The UKNNL, responsible for supporting national nuclear priorities, views the project as aligned with broader national objectives, including sustainable waste management and expanding nuclear capabilities. MDC, meanwhile, brings its radiochemistry and drug development expertise to ensure scientific readiness for clinical trials.
Together, the partners aim to establish a complete end-to-end ecosystem to accelerate the development of next-generation radiopharmaceuticals and provide long-term, reliable access to isotopes critical to cancer treatment.
Targeted Alpha Therapies remain an emerging area of oncology, but early research suggests they could address cancers that are currently resistant to treatment, due to the highly localised and potent nature of alpha-emitting isotopes like lead-212.
With government support and coordinated industrial investment, the UK initiative aims to bring these therapies to clinical trials and, ultimately, to hospitals across the country and abroad.
